Research Use Only · Not for Human Consumption 30% OFF EVERYTHING · limited time · Free Shipping on $250+ · View Lab Reports
Home / Peptide Library / Metabolic / Weight / Cagrilintide
Peptide Research Library

Cagrilintide

the long-acting amylin analogue
AM833, NNC0174-0833
For research use only Evidence grade B — multiple phase 1/2 human trials Metabolic / Weight

Cagrilintide (research codes AM833 / NNC0174-0833) is a long-acting analogue of the pancreatic hormone amylin, engineered with a C20 fatty-diacid lipidation to extend its half-life enough for once-weekly subcutaneous administration14. It has been studied in completed phase 1 and phase 2 randomized trials for weight management and type 2 diabetes, both alone and co-formulated with semaglutide (the combination is referred to in the literature as CagriSema)23. This page summarizes the published research record. Cagrilintide is offered strictly for research use only; it is not an approved drug, and no usage directions are provided here. All dosing figures below are quoted as administered in published human studies, not as recommendations.

Structure

Sequence & identity

Lys(γGlu-C20 diacid)-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (cyclic 3→8 disulfide) · C194H312N54O59S2 · 4409.01 g/mol

Structure and chemical identity verified against PubChem CID 171397054 (InChIKey LDERDVMBIYGIOI-IZVMHKDJSA-N)6. Cagrilintide is a lipidated, disulfide-bridged, C-terminally amidated peptide rather than a simple linear sequence.

What the research shows

Mechanisms studied

Amylin is a beta-cell hormone that researchers describe as contributing to satiety signaling. Cagrilintide is reported to act as a non-selective agonist at amylin and calcitonin receptors, engaging AMY1, AMY2, AMY3 and the calcitonin receptor1. In a mechanistic study, investigators reported that cagrilintide’s body-weight-lowering effect in mice depended on amylin receptors 1 and 3 (calcitonin receptor paired with RAMP1 and RAMP3): in RAMP1/3 knockout mice the weight-lowering effect was abolished and the peptide activated roughly 57% fewer neurons in the area postrema than in wild-type mice5. The molecule’s extended duration of action is attributed to a C20 eicosanedioic fatty-diacid attached via a gamma-glutamyl spacer, together with substitutions that researchers introduced to stabilize the central helix and reduce fibrillation relative to native human amylin4.

Reported in studies

Dosing in the research literature

The figures below summarise regimens as reported in published research — they are not recommendations or directions for use.

Source / modelRegimen reportedNotes
Lau et al., Lancet 2021 (phase 2, weight management)2Once-weekly subcutaneous cagrilintide at 0.3, 0.6, 1.2, 2.4 or 4.5 mg over 26 weeks (with up to 6 weeks of dose escalation), vs once-daily liraglutide 3.0 mg and placeboReported as administered in a dose-finding trial of 706 adults with overweight/obesity without diabetes; quoted for reference only, not as a usage direction.
Frias et al., Lancet 2023 (CagriSema phase 2, type 2 diabetes)3Once-weekly subcutaneous cagrilintide 2.4 mg co-administered with semaglutide 2.4 mg (CagriSema), each escalated to 2.4 mg, over 32 weeks, vs semaglutide 2.4 mg or cagrilintide 2.4 mg aloneAdults with type 2 diabetes (BMI >=27) on metformin +/- an SGLT2 inhibitor; figures reflect the published trial protocol only.
Enebo et al., Lancet 2021 (phase 1b PK)1Multiple ascending once-weekly doses of cagrilintide 0.16-4.5 mg co-administered with semaglutide 2.4 mgPharmacokinetic study reporting a cagrilintide half-life of 159-195 h, consistent with once-weekly administration.
Research use only. Peptigo products are sold to qualified researchers for laboratory use. This information summarises published research for reference and is not medical advice, a dosing recommendation, or directions for human or animal use.
Reported in studies

Effects observed in research

In the phase 2 monotherapy trial, researchers observed dose-dependent mean reductions in body weight from baseline of about 6.0% to 10.8% across the cagrilintide dose groups at 26 weeks, versus 3.0% with placebo and 9.0% with liraglutide 3.0 mg; the 4.5 mg group was reported as superior to liraglutide (10.8% vs 9.0%)2. In the CagriSema phase 2 trial in type 2 diabetes, investigators reported greater weight loss and improved glucose control with the combination than with either agent alone, including a continuous-glucose-monitoring time-in-range of 89% with CagriSema versus 76% with semaglutide and 72% with cagrilintide at week 323. Across these trials the most frequently reported adverse events were gastrointestinal (notably nausea, reported in roughly 20-47% of cagrilintide recipients in the phase 2 monotherapy study) and injection-site reactions2. A dedicated thorough-QT study in 105 healthy participants reported no clinically relevant QTc prolongation7.

Honest assessment

Strength of evidence

Grade B

Grade B. Cagrilintide has been evaluated in multiple completed, peer-reviewed phase 1 and phase 2 randomized controlled trials in humans, which consistently reported dose-dependent weight loss and, in combination with semaglutide, improved glycemic measures123. Evidence falls short of grade A because, as of this writing, published phase 3 outcome data were limited and cagrilintide is not an approved drug; long-term safety and efficacy remain under investigation. The receptor-level mechanistic findings cited here are derived from animal and in-vitro models5. No claims of treating, curing, or preventing any disease are made.

Handling

Reconstitution & storage

Reconstitute with bacteriostatic water for laboratory handling. Store lyophilised material frozen and reconstituted material refrigerated. Use Peptigo’s reconstitution calculator and storage cheat sheet for working figures.

References

References

  1. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. PMID: 33894838. https://pubmed.ncbi.nlm.nih.gov/33894838/
  2. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID: 34798060. https://pubmed.ncbi.nlm.nih.gov/34798060/
  3. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01163-7/abstract
  4. Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194. https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00565
  5. Carvas AO, Leuthardt A, Kulka P, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine. 2025. PMC12270663. https://pmc.ncbi.nlm.nih.gov/articles/PMC12270663/
  6. National Center for Biotechnology Information. PubChem Compound Summary for CID 171397054, Cagrilintide. https://pubchem.ncbi.nlm.nih.gov/compound/171397054
  7. Gabe MBN, Fuhr R, Sinn A, et al. Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes Obes Metab. 2024;26(12):5805-5811. PMID: 39279639. https://pubmed.ncbi.nlm.nih.gov/39279639/
Written by the Peptigo Research Team · scientifically reviewed by Peter, Peptigo Research Team · Last reviewed June 2026. We cite primary literature and flag where evidence is limited. Our sourcing & RUO policy →